| Â | Â | NEPC samples | AdCa samples | Gene-list |
|---|
Study | Type | U | M | L | P | U | M | L | P | GS | Up | Dn |
WCMC mCRPC | T | 10 | 10 | 3 | 2 | 25 | 18 | 9 | 7 | Â | 1226 | 1132 |
WCMC 2011 | T/Xa
| 7 | 6 | Â | 1 | 30 | Â | Â | 30 | 5-9 | 494 | 460 |
UW mCRPC | T | 6 | 7 | 3 | Â | 41 | 37 | 24 | Â | Â | 126 | 29 |
LuCaP xeno | X | 3 | 2 | 1 | 1 | 16 | 5 | 11 | 4 | Â | 17 | 16 |
MDA xeno | X | 3 | Â | 4 | 1 | 3 | Â | 1 | 2 | 9 | 45 | 67 |
VPC xeno | X | 1 | Â | Â | 1 | 6 | Â | 1 | 11 | Â | 254 | 185 |
VPC 2012 | T/X* | 1 | 3 | Â | Â | 3 | Â | 2 | 3 | 7-9 | 202 | 127 |
JHU 2009 | T | 1 | Â | Â | 1 | 1 | Â | Â | 1 | 7 | 41 | 41 |
Total | Â | 29 | Â | Â | Â | 114 | Â | Â | Â | Â | 1782 | 1785 |
- Legend: (Notation): U: unique patients, T: tumor, X: xenograft, P: primary, M: metastases, L: bladder, rectum, or lymph node, GS: Gleason score, Up/Dn: size of gene-lists up/down-expressed in NEPC. (a): WCMC 2011 and VPC 2012 each contained one xenograft NEPC sample. (Notes): WCMC studies shared 2 NEPC patients, while UW mCRPC and LuCaP studies shared 1 NEPC patient. Adenocarcinomas with NE differentiation were grouped with NEPCs in WCMC mCRPC, with adenocarcinomas in MDA xeno, and with either cohort in UW mCRPC depending on IHC status of chromogranin and synaptophysin (NEPC when both positive). The VPC xeno gene-list cross-referenced other studies and consisted of genes with expression changes following transdifferentiation in a xenograft model, concomitant alterations in the same direction prior to transdifferentiation relative to adenocarcinomas, and exhibiting the same trend in WCMC 2011. The JHU study consisted of a single patient tumor with adjacent small cell carcinoma and adenocarcinoma components
